Keros Therapeutics Inc. (KROS): Price and Financial Metrics

Keros Therapeutics Inc. (KROS): $68.85

1.35 (+2.00%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

D

Add KROS to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#329 of 360

in industry

KROS Price/Volume Stats

Current price $68.85 52-week high $73.00
Prev. close $67.50 52-week low $27.02
Day low $67.73 Volume 347,700
Day high $71.00 Avg. volume 475,233
50-day MA $53.06 Dividend yield N/A
200-day MA $40.53 Market Cap 2.48B

KROS Stock Price Chart Interactive Chart >


Keros Therapeutics Inc. (KROS) Company Bio


Keros Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on treatments for rare muscle diseases. The company was founded in 2015 and is headquartered in Lexington, MA.


KROS Latest News Stream


Event/Time News Detail
Loading, please wait...

KROS Latest Social Stream


Loading social stream, please wait...

View Full KROS Social Stream

Latest KROS News From Around the Web

Below are the latest news stories about KEROS THERAPEUTICS INC that investors may wish to consider to help them evaluate KROS as an investment opportunity.

Keros Therapeutics prices upsized stock offering to raise $140 million

More on Keros Therapeutics

HollySys Automation, Keros Therapeutics, and More Stocks See Action From Activist Investors

Activists report to the SEC on HireRight Holdings, HollySys Automation Technologies, Rover Group, Keros Therapeutics, and Beacon Roofing Supply

Yahoo | December 15, 2023

Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Yahoo | December 11, 2023

Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition

KER-050 (elritercept) achieved durable transfusion independence in lower-risk MDS, including in patients with high transfusion burdenDurable clinical responses were associated with improvements in patient-reported measures of fatigueBiomarker data demonstrate that KER-050 treatment has potential to reduce NT-proBNP a measure of cardiac stressPreliminary findings from ongoing Phase 2 clinical trial in myelofibrosis demonstrate that KER-050 can not only ameliorate ineffective hematopoiesis and add

Yahoo | December 11, 2023

Keros Therapeutics to Present at Upcoming Healthcare Conferences

LEXINGTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will present at the following healthcare

Yahoo | November 7, 2023

Read More 'KROS' Stories Here

KROS Price Returns

1-mo 20.33%
3-mo 124.71%
6-mo N/A
1-year 16.07%
3-year 19.47%
5-year N/A
YTD 73.16%
2023 -17.20%
2022 -17.93%
2021 -17.05%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!